Paclitaxel combined with platinum (PTX) versus fluorouracil combined with cisplatin (PF) in the treatment of unresectable esophageal cancer: a systematic review and meta-analysis of the efficacy and toxicity of two different regimens

Xu, Li’ang; Chen, Xiaoxi; Wang, Lan; Han, Jianda; Wang, Qi; Liu, Shutang; Zhang, Xiaolin; Han, Chun

doi:10.21037/jgo-23-33

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The animal model formed by the transplantation of human EC cells into nude mice is more similar to the characteristics of the transplanted tumor and the primary tumor (Cheng et al, 2023). Cisplatin is the first choice in the clinical treatment of EC (Xu et al, 2023), and the therapeutic effect is good, so we use cisplatin as a positive control drug. The results showed that the effect of EP was almost equivalent to that of cisplatin, but the group fed cisplatin is inactive.…”

Section: Discussionmentioning

confidence: 99%

Epinodosin suppresses the proliferation, invasion, and migration of esophageal squamous cell carcinoma by mediating miRNA‐143‐3p/Bcl‐2 axis

Chen,

Li,

Liu

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Epinodosin has shown antibacterial and antitumor biological characteristics in the documents. We found that Epinodosin has an effective inhibitory effect on esophageal squamous cell carcinoma (ESCC). However, the potential roles and mechanisms of Epinodosin in ESCC remain unclear. We performed many experiments to clarify the effect and mechanism of Epinodosin on ESCC. In this study, cell viability, invasion, migration, and apoptosis were determined by 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,‐diphenytetrazoliumromide (MTT), Transwell, and flow cytometry. The differentially expressed miRNAs were screened through RNA transcriptome sequencing. The expression levels of miRNA‐143‐3p and some proteins were measured by real‐time polymerase chain reaction (PCR) and Western blot. The anticancer effects of Epinodosin in vivo were determined by a nude mouse model. Epinodosin suppressed cell proliferation/invasion/migration and induced ESCC cell apoptosis. Epinodosin remarkably affected the protein expression of mitogen‐activated protein kinase (MAPK) signaling pathway. The animal experiments demonstrated that Epinodosin could attenuate the growth of ESCC tumors in nude mice. The expression of p53, Bim, and Bax was upregulated, while that of Bcl‐2 was downregulated in tumor tissues. In conclusion, Epinodosin suppresses cell viability/invasion/migration, while induces ESCC cell apoptosis by mediating miRNA‐143‐3p and Bcl‐2, and can markedly attenuate the growth of ESCC tumors in nude mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Epinodosin suppresses the proliferation, invasion, and migration of esophageal squamous cell carcinoma by mediating miRNA‐143‐3p/Bcl‐2 axis

Chen,

Li,

Liu

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Yet only a few rodent models exist for the study of PIPN including ours [28][29][30]. In recent studies, we have shown that paclitaxel administration drives altered behaviors including affective states and nociceptive responses such as mechanical allodynia and thermal hyperalgesia within mice [17,[31][32][33][34][35]. To understand the mechanism that may underlie these sensory responses, we assessed proteomic changes from the DRG in response to a paclitaxel treatment.…”

Section: Drg Proteomics Characterization In a Mouse Model Of Paclitax...mentioning

confidence: 99%

Proteomic Analysis of Dorsal Root Ganglia in a Mouse Model of Paclitaxel-Induced Neuropathic Pain

Hanna,

Graur,

Sinclair

et al. 2024

Preprint

View full text Add to dashboard Cite

Paclitaxel is a chemotherapy drug widely used for the treatment of various cancers based on its ability to potently stabilize cellular microtubules and block division in cancer cells. Paclitaxel-based treatment, however, accumulates in peripheral system sensory neurons and leads to a high incidence rate (over 60%) of chemotherapy induced peripheral neuropathy. Using an established preclinical model of paclitaxel-induced peripheral neuropathy (PIPN), we examined proteomic changes in dorsal root ganglia (DRG) of adult male mice that were treated with paclitaxel (8 mg/kg, at 4 injections every other day) relative to vehicle-treated mice. High throughput proteomics based on liquid chromatography electrospray ionization mass spectrometry identified 165 significantly altered proteins in lumbar DRG. Gene ontology enrichment and bioinformatic analysis revealed an effect of paclitaxel on pathways for mitochondrial regulation, axonal function, and inflammatory purinergic signaling as well as microtubule activity. These findings provide insight into molecular mechanisms that can contribute to PIPN in patients.

show abstract

“…In Asia, ESCC is a more common pathological type. Some studies have compared the efficacy of paclitaxel-based regimen and fluorouracil-based regimen in ESCC [ 7 – 10 ], but there is no consistent conclusion. In the era of immunotherapy, clinical studies have proved that chemotherapy combined with immune checkpoint inhibitors (PD-1 inhibitors) can confer greater benefit to patients with esophageal cancer than chemotherapy alone, especially in ESCC.…”

Section: Introductionmentioning

confidence: 99%

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis

Zhao,

Zhang,

Guo

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Background The combinations of PD-1 inhibitors with paclitaxel/cisplatinum (PD-1 + TP) and fluoropyrimidine/cisplatinum (PD-1 + FP) both have been shown to improve overall survival (OS) and progression-free survival (PFS) in patients with previously untreated, advanced esophageal squamous cell carcinoma (ESCC). However, there is no consensus on which chemotherapy regimen combined with PD-1 has better efficacy. To deal with this important issue in the first-line treatment of patients with ESCC, a network meta-analysis (NMA) was performed. Methods Data were collected from eligible studies searched in Medline, Web of Science, PubMed, the Cochrane Library and Embase. The pooled hazard ratio (HR) for the OS, and PFS, odds ratio (OR) for the objective response rate (ORR) and ≥ 3 grade treatment-related adverse events (≥ 3TRAEs) were estimated to evaluate the efficacy of PD-1 inhibitors combined with TP or FP. Results Five RCTs and one retrospective study involving 3685 patients and evaluating four treatments were included in this NMA. Compared to other treatments, PD-1 + TP was better. For the PFS, the HRs for PD-1 + TP compared to PD-1 + FP, TP and FP were 0.59 (0.44, 0.80), 0.56 (0.51, 0.61) and 0.45 (0.37, 0.56) respectively. For the OS, PD-1 + TP was also a better treatment compared to other treatments. The HRs were 0.74 (0.56, 0.96), 0.64 (0.57, 0.71), 0.53 (0.43, 0.67) respectively. For the ORR, there was no significant difference between PD-1 + TP and PD-1 + FP, and the ORs were 1.2 (0.69, 2.11). Compare with TP and FP, PD-1 + TP had an obvious advantage, ORs were 2.5 (2.04, 3.04) and 2.95 (1.91, 4.63). For ≥ 3TRAEs, PD-1 + TP compared to other treatments, ORs were 1.34 (0.74, 2.46) and 1.13 (0.92, 1.38) and 2.23 (1.35, 3.69). Conclusion PD-1 + TP significantly improved both PFS and OS compared to PD-1 + FP. Taking into account both efficacy and safety, PD-1 + TP may be a superior first-line treatment option for ESCC.

show abstract

Paclitaxel combined with platinum (PTX) versus fluorouracil combined with cisplatin (PF) in the treatment of unresectable esophageal cancer: a systematic review and meta-analysis of the efficacy and toxicity of two different regimens

Cited by 4 publications

References 19 publications

Epinodosin suppresses the proliferation, invasion, and migration of esophageal squamous cell carcinoma by mediating miRNA‐143‐3p/Bcl‐2 axis

Epinodosin suppresses the proliferation, invasion, and migration of esophageal squamous cell carcinoma by mediating miRNA‐143‐3p/Bcl‐2 axis

Proteomic Analysis of Dorsal Root Ganglia in a Mouse Model of Paclitaxel-Induced Neuropathic Pain

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis

Contact Info

Product

Resources

About